Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 3/20 | 0.61 |
| ▸ | CCNC | P24863 | 1/20 | 0.55 |
| ▸ | CDK8 | P49336 | 1/20 | 0.55 |
| ▸ | GAK | O14976 | 1/20 | 0.52 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.52 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.52 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | FERMT2 | Q96AC1 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CCR1 | P32246 | 1/20 | 0.47 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.47 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | FADS1 | O60427 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2455864 | 0.86 | CYP1A2 (0.68) | NR4A2CYP1A2FERMT2MAPTTDP1 | |
| SCHEMBL30028448 | 0.86 | CYP1A2 (0.68) | NR4A2CYP1A2FERMT2MAPTTDP1 | |
| Hydrochloric Acid SCHEMBL5680197 | 0.84 | CYP1A2 (0.66) | NR4A2CYP1A2FERMT2MAPTTDP1 | |
| SCHEMBL2480030 | 0.79 | CDK8 (0.60) | CCNCCDK8GAKRIPK2FERMT2 | |
| SCHEMBL21101482 | 0.76 | NR4A2 (1.00) | NR4A2CCNCCDK8GAKRIPK2 | |
| SCHEMBL1888577 | 0.75 | NR4A2 (0.66) | NR4A2CCNCCDK8GAKRIPK2 | |
| SCHEMBL30051309 | 0.75 | NR4A2 (0.66) | NR4A2CCNCCDK8GAKRIPK2 | |
| SCHEMBL3064565 | 0.75 | HTR1A (0.67) | GAKRIPK2COQ8ANLKCYP1A2 | |
| SCHEMBL248690 | 0.73 | HTR1A (0.63) | GAKRIPK2COQ8ANLKFERMT2 | |
| SCHEMBL28219975 | 0.72 | MAPKAPK2 (0.59) | CCNCCDK8GAKRIPK2COQ8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187455-B2 | Substituted pyridazines as PDE10A inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2015-11-17 | — | — | US | disclosed |
| EP-2398795-B1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-10-15 | — | — | EP | disclosed |
| CN-102239162-B | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2014-05-28 | — | — | CN | disclosed |
| EP-2373641-B1 | PYRIDAZINONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2012-12-19 | — | — | EP | disclosed |
| US-8178538-B2 | Pyridazinones | HOFFMANN-LA ROCHE INC. (US) | 2012-05-15 | — | — | US | disclosed |
| CN-102325766-A | Heteroaryl substituted pyridazinone derivatives | HOFFMANN LA ROCHE | 2012-01-18 | — | — | CN | disclosed |
| EP-2398795-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-12-28 | — | — | EP | disclosed |
| CN-102239162-A | Pyridazinone derivatives | HOFFMANN LA ROCHE | 2011-11-09 | — | — | CN | disclosed |
| EP-2373641-A1 | PYRIDAZINONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-10-12 | — | — | EP | disclosed |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| WO-2010094762-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100152193-A1 | PYRIDAZINONES | HOFFMANN-LA ROCHE, INC. | 2010-06-17 | — | — | US | disclosed |
| WO-2010063610-A1 | PYRIDAZINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152193-A1 | PYRIDAZINONES | PDE5A, PDE3A, PDE10A | NR4A2 1699/4885CCNC 3799/4885CDK8 2342/4885 |
| US-20100216793-A1 | HETEROARYL SUBSTITUTED PYRIDAZINONE DERIVATIVES | PDE3A, PDE10A, PDE5A | NR4A2 1667/4885CCNC 3491/4885CDK8 1957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.